Financials SUNE BIOP OTC Markets

Equities

SBFM

US8677812054

Pharmaceuticals

Delayed OTC Markets 16:15:16 05/10/2021 BST 5-day change 1st Jan Change
0.1175 USD -1.26% Intraday chart for SUNE BIOP +0.34% +657.96%

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 14.45 6.972 0.8946 -
Enterprise Value (EV) 1 14.45 6.972 0.8946 0.8946
P/E ratio -0.36 x -1.43 x 1.17 x 0.09 x
Yield - - - -
Capitalization / Revenue - 0.29 x 0.02 x 0.01 x
EV / Revenue - 0.29 x 0.02 x 0.01 x
EV / EBITDA - - - -
EV / FCF - - - -
FCF Yield - - - -
Price to Book - - - -
Nbr of stocks (in thousands) 226 257 994.5 -
Reference price 2 64.00 27.15 0.8995 0.8995
Announcement Date 04/04/23 28/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025
Net sales 1 - 24.09 44.4 100
EBITDA - - - -
EBIT 1 - -4.785 -0.237 12.06
Operating Margin - -19.86% -0.53% 12.06%
Earnings before Tax (EBT) 1 - -4.111 0.8431 12.99
Net income 1 -26.74 -4.506 0.6831 12.81
Net margin - -18.7% 1.54% 12.81%
EPS 2 -176.0 -19.00 0.7700 9.990
Free Cash Flow - - - -
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 04/04/23 28/03/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5.561 5.958 7.68 7 9 12.6 15.8
EBITDA - - - - - - -
EBIT 1 -0.9896 -0.7795 -1.187 -1.293 -0.613 0.3005 1.368
Operating Margin -17.8% -13.08% -15.46% -18.47% -6.81% 2.38% 8.66%
Earnings before Tax (EBT) 1 -0.8144 -0.6105 -1.03 -1.013 -0.343 0.5705 1.629
Net income 1 -0.9021 -0.6515 -1.25 -1.053 -0.383 0.5305 1.589
Net margin -16.22% -10.94% -16.28% -15.04% -4.26% 4.21% 10.05%
EPS 2 -2.000 -4.000 -5.700 -1.040 -0.3700 0.4500 1.340
Dividend per Share - - - - - - -
Announcement Date 10/08/23 13/11/23 28/03/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - - -
ROE (net income / shareholders' equity) - - - -
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share - - - -
Cash Flow per Share - - - -
Capex - - - -
Capex / Sales - - - -
Announcement Date 04/04/23 28/03/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8995 USD
Average target price
15 USD
Spread / Average Target
+1,567.59%
Consensus